Beyond rituximab, the engineered anti-CD20 mAb obinutuzumab is registered and employed in combination with chemotherapy as first-line therapy for defined cases of CLL and FL. The gene discussed is MS4A1; the disease is B-cell chronic lymphocytic leukemia.